Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

The Jefferson County Senior Services Division is hosting The MMRF Multiple Myeloma Community Connect event on Thursday, Nov.

In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better. Receiving the once-weekly KRd56 treatment ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

Sharda Sinha's battle with Multiple Myeloma highlights the disease's dangers. Learn about its impact and significance.- Watch ...